hims glp 1 states & Hers stock crashes after FDA announces plans to take "decisive steps" against GLP-1 compounds Hims & Hers Health will

Who Profits: Eli Lilly (LLY) FY2025 Revenue: $63.5B | GLP-1 Revenue (Mounjaro + Zepbound): $35-38B (estimated) | Operating Margin: 31% | CEO (David Ricks): $24.3M This issue's mechanism: Eli Lilly is winning the market share battle against Novo

News provided by Phenomix Sciences May 07, 2025, 09:03 ET Study presented at DDW 2025 finds genetic risk scores can identify patients at higher risk of nausea from GLP-1 therapies, supporting the development of more targeted treatment decisions and advancing pharmaceutical R&D

BaiSWenWHouXWuJYiLZhiYet al

In 3% of patients with severe acute pancreatitis, flank ecchymosis (Grey Turner sign) or periumbilical ecchymosis (Cullen sign) develops and is suggestive of retroperitoneal hemorrhage